Top 10 Services Companies To Buy For 2015

Despite a week shortened by Presidents' Day, the number of insider transactions, as defined by the number of companies, rose for the third straight week. �It's nice to see boardroom confidence on the rise in the face of stumbling economic reports. Hopefully, the spate of underwhelming news is temporary.

As is it is every week, iStock found a company within the list of transactions worthy of further discussion. Today, we find some interest with Janus Capital Group, Inc. (JNS).

Janus Capital Group is a publicly owned asset management holding company with approximately $167.7 billion in assets under management. It also provides retirement planning, investment planning, tax planning, investment for college, and tax planning services to its clients. The firm primarily provides its services to investment companies, retail investors, institutions, and individuals.

Top 10 Services Companies To Buy For 2015: Steiner Leisure Limited(STNR)

Steiner Leisure Limited provides spa services and personal care products for men, women, and teenagers worldwide. The company offers beauty care products, including cleansers, toners, moisturizers, lotions, waxing products, cleansing accessories, and other skin care and body products, as well as aromatherapy oils and beauty tools; and hair care products, such as shampoos, conditioners, styling products, and related items. Its services include massages, facials, microdermabrasion, waxing, aromatherapy treatments, seaweed wraps, aerobic exercise, yoga, pilates, hair styling, manicures, pedicures, and teeth whitening, as well as various other beauty and body treatments and services; acupuncture; and medi-spa services comprising BOTOX Cosmetic, Dysport, Restylane, and Perlane. In addition, the company operates approximately 12 post-secondary schools, which provide education in massage therapy, beauty, skin care, and related areas at 30 campuses in 14 states. Further, it provid es procedures for the removal of unwanted facial and body hair in a clinical setting. The company offers its products and services under the Elemis, La Th�apie, Bliss, Rem�e, Laboratoire Rem�e, Mandara Spa, Mandara, Jou, and Chavana brands through department stores; third party retail outlets; distributors; salons; mail orders; and company owned Websites, including www.timetospa.com, www.timetospa.co.uk, www.blissworld.com, www.blisslondon.co.uk, and www.bodyworkmall.com, as well as through the QVC home shopping television channel. As of February 13, 2012, it served 152 cruise ships representing 19 cruise lines; and operated 54 resort spas, 11 urban hotel spas, 6 day spas, and 59 ideal image laser hair removal centers. Steiner Leisure Limited was founded in 1934 and is based in Nassau, the Bahamas.

Advisors' Opinion:

• [By Rick Munarriz]

  Royal Caribbean,�NCL (NYSE: NCL  ) , and ship spa services provider Steiner Leisure (NASDAQ: STNR  ) all hit new 52-week highs earlier this month. Unlike Carnival (NYSE: CCL  ) -- which has been sluggish in light of several mishaps at sea since last year -- everyone seemed to view the negative instances as Carnival-specific events. Now Royal Caribbean's fire may lead folks to question booking on any cruise line in the near future.

Top 10 Services Companies To Buy For 2015: Swisher Hygiene Inc.(SWSH)

Swisher Hygiene Inc. provides hygiene and sanitation solutions in North America and internationally. Its solutions include cleaning and sanitizing products and services designed to promote cleanliness and sanitation in commercial and residential environments. The company involves in the sale of consumable products, such as soaps, paper, cleaning chemicals, detergents, and supplies, together with the rental and servicing of dish machines and other equipment for the dispensing of those products; sale and rental of facility service items requiring regular maintenance and cleaning, such as floor mats, mops, and bar towels; provision of manual cleaning services for facilities; and provision of solid waste collection services. It serves customers in a range of end-markets, including foodservice, hospitality, retail, industrial, and healthcare industries. Swisher Hygiene Inc. offers its services through 69 company owned operations and 10 franchise operations located throughout th e United States and Canada; and through 10 master license agreements covering the United Kingdom, Ireland, Portugal, the Netherlands, Singapore, the Philippines, Taiwan, Korea, Hong Kong, Macau, China, and Mexico. The company was founded in 1986 and is headquartered in Charlotte, North Carolina.

Advisors' Opinion:

• [By Lisa Levin]

  Swisher Hygiene (NASDAQ: SWSH) shares touched a new 52-week low of $0.55. Swisher shares have dropped 51.30% over the past 52 weeks, while the S&P 500 index has gained 31.68% in the same period.

• [By Lisa Levin]

  Swisher Hygiene (NASDAQ: SWSH) shares touched a new 52-week low of $0.732. Swisher Hygiene appointed William Pierce as its new president and CEO.

  Territorial Bancorp (NASDAQ: TBNK) shares touched a new 52-week low of $21.31. Territorial Bancorp shares have dropped 9.43% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.

Top 10 Dividend Companies To Buy Right Now: Kinder Morgan Management LLC (KMR)

Kinder Morgan Management, LLC is a limited partner in Kinder Morgan Energy Partners, L.P (KMP), and manages and controls its business and affairs pursuant to a delegation of control agreement. Kinder Morgan G.P., Inc., of which Kinder Morgan, Inc. indirectly owns all of the outstanding common equity, is the general partner of Kinder Morgan Energy Partners, L.P. (KMP). Kinder Morgan G.P., Inc., pursuant to a delegation of control agreement among the Company, Kinder Morgan G.P., Inc. and KMP, has delegated to the Company, to the fullest extent permitted under Delaware law and KMP�� limited partnership agreement, all of its rights and powers to manage and control the business and affairs of KMP, subject to the general partner�� right to approve specified actions.

KPM is a pipeline limited partnerships in the United States. KMP owns an investment in or operates approximately 28,000 miles of pipelines and 180 terminals. Its pipelines transport products, such as natural gas, crude oil, gasoline, and CO2, and its terminals store petroleum products and chemicals and handle materials like coal. Almost all of Kinder Morgan assets are owned by KMP, KMP operates in five business segments : Natural Gas Pipelines, Products Pipelines, CO2, Terminals and Kinder Morgan Canada.

Kinder Morgan is a transporter and marketer of carbon dioxide in North America. It delivers approximately 1.3 billion cubic feet per day of CO2 through about 1,300 miles of pipelines. It is an oil producer in Texas, producing over 55,000 barrels of oil per day at the SACROC Unit and the Yates Field in the Permian Basin. In addition to CO2 pipelines and oil producing fields, this business segment owns interests in and operates CO2 source fields, natural gas and gasoline processing plants, and a crude oil pipeline. Kinder Morgan owns and operates approximately 24,000 miles of gas pipelines in the Rocky Mountains, the Midwest and Texas. Through its Products Pipelines business unit, it transports over two million barre! ls per day of gasoline, jet fuel, diesel, natural gas liquids and other fuels through more than 8,000 miles of pipelines. The Company also has approximately 50 liquids terminals in this business segment that store fuels and offer blending services for ethanol and other products.

Kinder Morgan have more than 180 terminals that store petroleum products and chemicals, and handle bulk materials like coal, petroleum coke and steel products. Kinder Morgan operates a number of pipeline systems and terminal facilities in Canada including the Trans Mountain pipeline, the Express and Platte pipelines, the Cochin pipeline, the Puget Sound and the Trans Mountain Jet Fuel pipelines, the Westridge marine terminal, the Vancouver Wharves terminal in British Columbia and the North Forty terminal in Edmonton, Alberta.

Advisors' Opinion:

• [By Dan Caplinger]

  Kinder Morgan (NYSE: KMI  ) will release its quarterly report on Wednesday, and investors have high expectations for growth from the company. With its ownership interest in Kinder Morgan Energy Partners (NYSE: KMP  ) and Kinder Morgan Management (NYSE: KMR  ) , Kinder Morgan continues to take advantage of the need for energy producers to transport their oil and gas to market.

• [By Matt DiLallo]

  Kinder Morgan offers investors four ways to invest. In addition to the parent company, Kinder Morgan, investors can also choose to invest in MLPs Kinder Morgan Partners and El Paso Pipeline Partners or Kinder Morgan Management (NYSE: KMR  ) . Both of the partnerships directly own the pipeline and other midstream assets and offer higher yields. Meanwhile, the management company offers a tax-friendly way to invest in Kinder Morgan Partners with one key difference: Investors are paid in shares instead of cash. No matter which option you choose, Kinder Morgan is a top company whose stock, or units, are a great holding for any portfolio.

Top 10 Services Companies To Buy For 2015: TechnoConcepts Inc (TCPS)

TechnoConcepts, Inc. (TCI), incorporated in May 2003, is in the business of designing, developing, manufacturing and marketing wireless communications semiconductors. The Company has begun manufacturing wireless transmitter and receiver microchips, based on its technology, and produced its engineering run in August 2006. The technology, which TCI calls True Software Radio, is designed to improve the way that wireless signals are received and transmitted, by making possible device-to-device communication across otherwise incompatible networks and wireless standards. On October 17, 2005, the Company, through its wholly owned subsidiary, Asante Acquisition Corp. completed reorganization with RegalTech Inc. RegalTech's name was changed to Asante Networks Inc. (Asante).

In December 2005, the Company formed Jinshilin Techno Ltd. (Jinshilin Techno) as its wholly owned subsidiary based in Shanghai, China. The Company organized Jinshilin Techno to provide marketing, sales and technical support for True Software Radio technology in China. On April 21, 2006, Jinshilin Techno acquired Internet television (IPTV) set-top box (STB) technology through license agreements with Jinshilin Technologies Development Company Ltd. (Jinshilin). Jinshilin Techno offers an IPTV set-top box that features voice over Internet protocol (VOIP), capability and can receive Internet protocol (IP) data transmissions through the household electrical power grid.

Asante Networks Inc. provides Ethernet networking solutions for Apple Computer and the small-to-medium business retail markets, offering the IntraCore and FriendlyNET product families, integrating voice, data, and video over wireless and wired networks with unified management and authentication. In April 2006, Asante announced the release of 2-chip switch solution, the IntraCore 38480. The IntraCore 38480 provides no frame loss and full-wire speed with minimized latency. With 96-gigabit switching fabric, the IntraCore 38480 supports full-wire speed on all ! ports. It has advanced traffic control based on L2-L7 data of incoming frames.

The Company's True Software Radio technology makes possible for wireless transmitters and receivers, as well as the radio signal processing, to be fully controlled and reconfigured by software commands across a range of frequencies and frequency bands. Its True Software Radio technology is a delta-sigma microchip architecture that converts radio frequency signals directly into digital data for the wireless receiver and directly from digital data into radio signals for the wireless transmitter. True Software Radio microchips replace the analog front end, intermediate frequency (I/F) processing, analog-to-digital conversion (ADC), and digital filtering sections of conventional wireless transmitters and receivers.

Advisors' Opinion:

• [By Peter Graham]

  Small cap tech stocks TechnoConcepts, Inc (OTCMKTS: TCPS), Unisource Corporation (OTCMKTS: USRC) and Strategic Global Investments, Inc (OTCMKTS: STBV) have been getting some attention lately in various investment newsletters thanks to promotions. Of course, there is nothing wrong with properly disclosed promotions, but they can backfire on the unwary as its really up to investors or traders alike to do their own due diligence before investing or trading. With that in mind, here is a quick reality check about three small cap tech stocks getting a bit of attention lately:

  TechnoConcepts, Inc (OTCMKTS: TCPS) Has the Yield Sign Replaced on Its OTC Page

  Small cap TechnoConcepts is a wireless technology company currently holding patents and other intellectual property. On Friday, TechnoConcepts fell 0.45% to $15.58 for a market cap of $415.28 million plus TCPC is up 1.1% over the past year and up 6% since April 2012 according to Google Finance.

Top 10 Services Companies To Buy For 2015: Alliance Creative Group Inc (ACGX)

Alliance Creative Group Inc. (ACG), incorporated on June 1, 2000, is a printing, packaging, product development, management, marketing and consulting company. The Company comprises of five key components: Creative & Design, Printing & Packaging, Product Development, Event Marketing and Business Consulting & Strategic Marketing. It maintains and operates six Websites, including: alliancecreativegroup.com, stlouispackaging.com, stlgraphics.com, snapgraphics.com, IMAGEchicago.com and TicketHotLink.com.

Creative & Design

The Company offers graphic design services. It specializes in print and Web design solutions. The Company�� Creative & Design services include advertising campaigns, brand identity, brochures, business cards, catalogs, direct mail, flyers, logos, manuals/media kit, marketing materials, package design, POP display, postcards, PowerPoint template design, sales kit, stationary and Websites.

Printing & Packaging

Printing & Packaging

The Company�� printing division, STL Graphics Group offers printing services from design to delivery. Snap Graphics is a commercial printing company specializing in off-set, large format, silk screen, and digital printing. It printing services include design support, digital printing, direct mail, inventory management, mailing services, media, packaging, sheet-fed, and Web. The Company�� Bindery services include collating, drilling, folding, GBC binding, padding, saddle stitching and tabbing. Its Logistics services include local, regional, and national warehousing, inventory control and analysis, multi carrier freight, auto replenishment, automated and manual pick and pack, around-the-clock distribution, order tracking, assembly and kit building, order consolidation and direct field requisition.

The Packaging division at ACG (St. Louis Packaging) provides a variety of solutions. It offers options catered to individual needs, as well as over 10,000 stock supplies for everyday use. It offe! rs a range of standard supplies used in everyday packing and shipping, from corrugated boxes to fasteners and adhesive. The Company offers over 10,000 products from brands, such as 3M, Sealed Air, Intertape, Rubbermaid and Ivex. St. Louis Packaging offers a variety of products, including recycled cartons, recycled stuffing and wrapping papers and recycled polyethylene.

Product Development

Alliance Creative Group has created a product development division focused on getting products to retail and building brand equity for clients. ACG offers services in every phase of the product life cycle, including creation, marketing, placement, distribution and management. It offers services, such as product creation, product marketing, product placement, product distribution and brand management.

Event Marketing

The Company�� event marketing division has experience in strategy, creative, production, promotion, execution, and evaluation of events ranging from 20-4000 attendees. Its services include Creative design, Entertainment, Email blasts, Event planning and marketing, Event strategy, Food and drinks, Mobile marketing, Partnerships, Site selection and venue contacting Survey and evaluation, Theme development and Ticket Brokering.

Business Consulting & Strategic Marketing

Alliance Creative Group (ACG) is the Company�� consulting division. The division offers business advisory, consulting and marketing services. ACG develops business and marketing plans, draft press releases, create and maintain social media campaigns, provide funding, make introductions to investment bankers or other funding and take companies public. ACG helps with Business Development, Strategic Planning, Marketing and Product Development.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Alliance Creative Group Inc (OTCMKTS: ACGX), Dale Jarrett Racing Adventure Inc (OTCMKTS: DJRT), Inscor Inc (OTCMKTS: IOGA) and Solar Thin Films Inc (OTCMKTS: SLTZ) have all been getting some attention lately in various investment newsletters and it should come as no surprise that two out of four of these stocks have been the subject of paid promotions ��which tend to benefit traders. However, two out of four of these stocks also have pretty good financials for being small cap OTC stocks and that might make them attractive to investors with a long term time horizon. So which of these stocks might make traders some profits in the short term and investors some profits over the longer term? Here is a closer look to help you decide:

Top 10 Services Companies To Buy For 2015: Vail Resorts Inc. (MTN)

Vail Resorts, Inc., through its subsidiaries, operates resorts in the United States. The company operates in three segments: Mountain, Lodging, and Real Estate. The Mountain segment operates eight ski resort properties, including the Vail Mountain, Breckenridge Ski, Keystone, Beaver Creek, Heavenly Mountain, Northstar, Kirkwood Mountain, and Canyons resorts; and two urban ski areas, such as Afton Alps and Mount Brighton Ski areas, as well as provides ancillary services, primarily ski school, dining, and retail/rental operations. Its resorts offer various recreational activities comprising skiing, snowboarding, snowshoeing, snowtubing, sightseeing, mountain biking, guided hiking, children's activities, and other recreational activities, as well as ski and snowboard lessons, equipment rental and retail merchandise services, dining venues, and private club services. This segment also leases its owned and leased commercial space; and provides real estate brokerage services. Th e Lodging segment owns and/or manages a collection of luxury hotels under the RockResorts brand, and other lodging properties; various condominiums located in and around the company�s ski resorts; destination resorts; and golf courses, as well as offers resort ground transportation services. This segment operates approximately 5,100 owned and managed hotel and condominium rooms. The Real Estate segment owns, develops, markets, and sells real estate properties in and around the company�s resort communities. Vail Resorts, Inc. was founded in 1997 and is based in Broomfield, Colorado.

Advisors' Opinion:

• [By Laura Brodbeck]

  Next week investors will be waiting for several key earnings reports including Aeropostale Inc. (NYSE: ARO), Caesars Entertainment Corporation (NASDAQ: CZR), Vail Resorts, Inc. (NYSE: MTN), Williams-Sonoma, Inc (NYSE: WSM).

Top 10 Services Companies To Buy For 2015: Grupo Casa Saba S.A. de C.V.(SAB)

Grupo Casa Saba, S.A.B. de C.V., through its subsidiaries, operates as a multi-channel and multi-product wholesale distributor primarily in Mexico. It distributes pharmaceutical products; health and beauty aids; publication products, such as magazines, books, albums, and stickers; food and non-perishable products; personal care and consumer goods; and general merchandise. The company also sells pharmaceutical products through its Farmacias ABC pharmacy chain located in Guadalajara, Jalisco; Farmacias Provee de Especialidades primarily located in Monterrey and Nuevo Leon of Mexico, as well as in the states of Chihuahua and Coahuila; and through Farmacias Benavides. In addition, it provides freight services to third parties. Further, it operates medical clinics; and offers specialized medical, rehabilitation, and surgical services, as well as provides real estate services. The company serves pharmacies, mass merchandisers, retail and convenience stores, specialty stores, sup ermarkets, and other specialized channels. As of December 31, 2010, it operated a distribution network consisting of 22 active distribution centers. It also operates in Brazil, Chile, and Peru. Grupo Casa Saba, S.A.B. de C.V. was founded in 1892 and is based in Mexico, Mexico.

Advisors' Opinion:

• [By Sofia Horta e Costa]

  SABMiller Plc (SAB), the world�� second-biggest brewer, dropped 2.1 percent to 3,165 pence. Credit Suisse Group AG cut its rating on the beverage industry to benchmark, similar to neutral, from overweight, citing valuations. The Stoxx 600 Food & Beverage Index trades at 18.2 times projected earnings, compared with 14.3 times profit for the broader gauge, according to data compiled by Bloomberg.

• [By Inyoung Hwang]

  U.K. stocks erased losses in the last half hour of trading, leaving the FTSE 100 Index (UKX) little changed, as a rally in British Sky Broadcasting Group Plc (BSY) and SABMiller Plc (SAB) offset Dagong Global Credit Rating Co.�� downgrade of U.S. sovereign debt.

• [By Tom Stoukas]

  SABMiller Plc (SAB) lost 2.1 percent to 3,462 pence. The world�� second-largest brewer said earnings before interest, taxes and amortization in the year to March 31 rose to $6.42 billion. That missed the median estimate of 13 analysts in a Bloomberg News survey that called for $6.46 billion.

Top 10 Services Companies To Buy For 2015: ATA Inc.(ATAI)

ATA Inc., through its subsidiaries, provides computer-based testing services in the People?s Republic of China. It offers services for the creation and delivery of computer-based tests utilizing its test delivery platform, proprietary testing technologies, and testing services; and provides logistical support services relating to test administration. The company?s computer-based testing services are used for professional licensure and certification tests in various industries, including information technology (IT) services, banking, securities, teaching, and insurance. Its e-testing platform integrates various aspects of the test delivery process for computer-based tests ranging from test form compilation to test scoring, and results analysis. ATA also provides career-oriented educational services, such as single course programs, degree major course programs, and pre-occupational training programs focusing on preparing students to pass IT and other vocational certification tests; test preparation and training programs and services to test candidates preparing to take professional certification tests in securities, futures, banking, insurance and teaching industries; online test preparation and training platform for the securities and banking industries; and test preparation software for the teaching industry. In addition, the company offers HR select employee assessment solution, an online system that utilizes its proprietary software and an inventory of test titles to help employers improve the efficiency and accuracy of their employee recruitment process. As of March 31, 2010, it had contractual relationships with 1,988 ATA authorized test centers. The company serves Chinese governmental agencies, professional associations, IT vendors, and Chinese educational institutions, as well as individual test preparation services. ATA Inc. was founded in 1999 and is based in Beijing, the People?s Republic of China.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Industrials stocks gained Friday, with ATA (NASDAQ: ATAI) leading advancers. Meanwhile, gainers in the sector included Plug Power (NASDAQ: PLUG), with shares up 22 percent, and Korn/Ferry International (KFY), with shares up 12 percent. In trading on Friday, basic materials shares were relative laggards, down on the day by about 1.36 percent.

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Industrials stocks gained Friday, with ATA (NASDAQ: ATAI) leading advancers. Meanwhile, gainers in the sector included Plug Power (NASDAQ: PLUG), with shares up 22 percent, and Korn/Ferry International (KFY), with shares up 12 percent. In trading on Friday, basic materials shares were relative laggards, down on the day by about 1.36 percent.

Top 10 Services Companies To Buy For 2015: Duckwall-Alco Stores Inc.(DUCK)

Duckwall-ALCO Stores, Inc. operates as a regional broad line retailer in the central United States. The company operates ALCO stores that offer a line of merchandise consisting of approximately 35,000 items, including automotive, commodities, crafts, domestics, electronics, furniture, hardware, health and beauty aids, housewares, jewelry, pre-recorded music and video, sporting goods, seasonal items, stationery, and toys, as well as ladies?, men?s, and children?s apparel and shoes. As of March 1, 2012, it operated 216 ALCO stores in 23 states. The company was founded in 1901 and is based in Abilene, Kansas.

Advisors' Opinion:

• [By Geoff Gannon]

  Stocks trading at or below book value ��not counting goodwill ��are the easiest to understand. Whether we are talking about DreamWorks or Avalon Holdings or Duckwall ALCO (DUCK) or J.W. Mays (MAYS), if a stock is trading around book value your next step is to figure out how book value is calculated.

Top 10 Services Companies To Buy For 2015: Genco Shipping & Trading Limited (GNK)

Genco Shipping & Trading Limited engages in the ocean transportation of drybulk cargoes through the ownership and operation of drybulk carrier vessels worldwide. It transports iron ore, coal, grain, steel products, and other drybulk cargoes. The company charters its vessels primarily to trading houses, which include commodities traders; producers; and government-owned entities. Its fleet consists of 53 drybulk carriers, including 9 Capesize, 8 Panamax, 17 Supramax, 6 Handymax, and 13 Handysize drybulk carriers with an aggregate carrying capacity of approximately 3,810,000 dwt. The company, through its subsidiary, Baltic Trading Limited, operates a fleet of two Capesize, four Supramax, and three Handysize drybulk carriers with an aggregate carrying capacity of approximately 672,000 dwt. Genco Shipping & Trading Limited was incorporated in 2004 and is based in New York, New York.

Advisors' Opinion:

• [By silvmich]

  This is Part Three of a series of articles published on GuruFocus outlining a short thesis against Genco Shipping and Trading (GNK). Part One was published on October 31, 2013 and Part Two was published on November 14, 2013. This Part Three provides certain updates on the situation, including recent news items, as well as a look into a number of counterarguments made against the short position.

• [By FinanceGuru]

  The second contrarian indicator is that the short interest in DryShips has increased significantly. They're topped only now by Genco Shipping (GNK), which is currently poised to be heading into bankruptcy.

Top Biotech Stocks To Buy Right Now

Recent news surrounding small cap biotech stocks like�Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),�Puma Biotechnology Inc (NYSE: PBYI),�Geron Corporation (NASDAQ: GERN)
and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech�IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends:

Biotech IPOs Cool. All five biotech offerings planned for the week of November 18 were postponed while a�biotech IPO for Tuesday priced at the low end of expectations. However,�trouble for biotech IPOs�actually began in September when�a potential treatment for Duchenne muscular dystrophy from small cap�Prosensa Holding NV failed in a late-stage study. Prosensa Holding NV had only�gone public in June and is now down some 76%:

Top Biotech Stocks To Buy Right Now: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

Top Biotech Stocks To Buy Right Now: International Stem Cell Corp (ISCO)

International Stem Cell Corporation, incorporated on June 7, 2005 is a developmental-stage biotechnology company. The Company focused on therapeutic and biomedical product development. The Company�� wholly owned subsidiary Lifeline Cell Technology, LLC (LCT) develops, manufactures and commercializes over 130 human cell culture products, including frozen human primary cells and the reagents (media) needed to grow, maintain and differentiate the cells, in order to address this market opportunity. The Company�� scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. The Company�� wholly owned subsidiary Lifeline Skin Care, Inc. (LSC) develops, manufactures and markets cosmetic skin care products using an extract derived from its pluripotent stem cells.

Therapeutic Product Candidates

Using the Company's technologies and know-how, the Company is exploring and creating a range of cell types that is useful in therapeutic treatments, which include Liver cells (hepatocytes) that may be used to treat a range of congenital and acquired liver diseases. Neuronal cells for potential treatment of Parkinson's disease and other central nervous system disorders, such as traumatic brain injury, stroke and Alzheimer�� disease. Three-dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to accelerate corneal healing.

Skin Care Products

The Company�� research scientists developed two skin care products, Defensive Day Serum and Recovery Night Serum, using an extract derived from human parthenogenic stem cells. Defensive Serum contains sunscreen, along with stem cell-derived ingredients. The day serum not only protects the skin from the aging effects of harsh light, but it continues to nurture the skin�� collagen and fibroblasts to give noticeably firmer, smoother, younger-looking ! skin. The Recovery Night Serum is a nighttime therapy that complements the Defensive Day Serum. The night serum nurtures the skin�� collagen and elastin and contains ingredients to defend against damaging free radicals, to help build firmer, smoother, younger and healthier-looking skin.

Research Products

The Company�� Lifeline subsidiary produces and sells over 250 human cell culture products. These products include frozen human cells and stem cells and the reagents needed to grow, maintain and differentiate the cells. These human cell-based products are used domestically and internationally by research scientists in pharmaceutical, academic and government research organizations to study human disease and basic cell biology.

The Company competes with Genzyme Corporation, StemCell, Advanced Cell Technology Inc., Aastrom Biosciences, ViaCyte, Obagi, SkinCeuticals, SkinMedica, Murad, Lonza, Chemicon, Life Technologies, StemCell Technologies, Merck, BioTime and Specialty Media.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:

• [By John Udovich]

  From stem cell burgers to earnings reports, the stem cell industry and small cap players in it like NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been producing some news lately that has probably been overlooked by investors and traders alike given its August. Nevertheless, you might want to pay attention to the following stem cell news:

Hot Freight Companies To Invest In Right Now: Intrexon Corp (XON)

Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.

The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.

The UltraVector gene design and fabrication platform

The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.

UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.

Cell Systems Informatics

The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.

The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.

LEAP-cell identification and selection

The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.

mAbLogix- antibody discovery

The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.

The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.

Advisors' Opinion:

• [By John Udovich]

  Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

Top Biotech Stocks To Buy Right Now: Pain Therapeutics Inc (PTIE)

Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.

REMOXY

REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.

Metastatic Melanoma

The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.

Hemophilia

The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).

Other product candidates

The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.

The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.

Advisors' Opinion:

• [By Jessica Alling]

  Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE  ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.

• [By Sean Williams]

  However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE  ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE  ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.

Top Biotech Stocks To Buy Right Now: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By John Udovich]

  Small cap cancer stock Ariad Pharmaceuticals, Inc (NASDAQ: ARIA) got annihilated yesterday on bad news which seemed to spread like a virus through other biotech stocks, but not all the recent�news surrounding cancer or both large cap and small cap cancer stocks has been�bad as there is good news coming from AstraZeneca plc (NYSE: AZN), Celgene Corporation (NASDAQ: CELG) and MetaStat Inc (OTCMKTS: MTST). Moreover, many investors are distracted by the sideshow going on in Washington DC and may not be paying attention to the following news, good or bad, surrounding the cancer space or cancer stocks:

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By Ben Levisohn]

  No, says Credit Suisse analyst Ravi Mehrotra and team, when contemplating the recent drops in Gilead Sciences (GILD), Biogen Idec (BIIB),�Celgene (CELG) and their ilk. They explain why:

Best Medical Stocks For 2015

Obesity experts say the recall of the over-the-counter fat-blocking diet pill Alli is a setback for dieters.

The maker of Alli (pronounced AL-eye) is voluntarily recalling all the weight loss products from U.S. and Puerto Rico retailers because the company believes that some packages of the product were tampered with and may contain product that is not authentic.

GlaxoSmithKline (GSK) Consumer Healthcare said it received inquiries from consumers in seven states about bottles of Alli that contained tablets and capsules that were not the weight-loss product. Alli, a non-prescription version of the drug orlistat, prevents about 25% of fat from being absorbed by the intestines.

This is a real setback for patients and doctors who are trying to manage weight to improve health, says obesity researcher Donna Ryan, professor emeritus at the Pennington Biomedical Research Center in Baton Rouge. "From a patient perspective, it is a loss. Patients say the medication works. It helps them avoid tempting high-fat meals and snacks.

Best Medical Stocks For 2015: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

  Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Best Medical Stocks For 2015: Conmed Corp (CNMD)

CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.

Arthroscopy

The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.

Powered Surgical Instruments

Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.

The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.

The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.

Electrosurgery

The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.

Patient Care

The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.

Endosurgery

Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.

Endoscopic Technologies

The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.

The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.

The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.

Advisors' Opinion:

• [By Seth Jayson]

  Margins matter. The more CONMED (Nasdaq: CNMD  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong CONMED's competitive position could be.

• [By James Brumley]

  Shares of MDT stock have fallen 6% since their early January peak, but have been in an uptrend since late 2011 … one of the few stocks in the medical device world that has been rock-solid in a rocky environment.

  Medical Devices: ConMed Corp. (CNMD)

  With a market cap of only $1.2 billion, ConMed Corp. (CNMD) isn’t exactly a household name. That doesn’t mean CNMD stock can’t be a potent addiction to a portfolio, though.

Best Low Price Companies To Invest In Right Now: CryoLife Inc (CRY)

CryoLife, Inc. (CryoLife,), incorporated in January 19,1984, is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using CryoLife�� SynerGraft technology. The Company operates in two segments: preservation services and medical devices segment. The preservation services segment includes services revenues from the preservation of cardiac and vascular tissues during the year ended December 31, 2011. The medical devices segment includes revenues from product sales of BioGlue, BioFoam, PerClot, HemoStase and revascularization technologies, as well as sales of other medical devices. CryoLife�� surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam) and PerClot, an absorbable powdered hemostat. In May 2011, it acquired Cardiogenesis Corporation. In May 2012, the Company acquired Hemosphere, Inc. Hemosphere develops and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. In February 2014, CryoLife Inc announced the establishment of CryoLife Asia Pacific Pte. Ltd.

CryoLife distributes preserved human cardiac and vascular tissues to implanting institutions throughout the United States (U.S), Canada and Europe. CryoLife processes and preserves cardiac and vascular tissues using processing and freezing techniques, or cryopreservation. The Company�� preservation process involves the recovery of tissue from deceased human donors by tissue banks and organ procurement organizations (OTPOs), the delivery, of such tissue to the Company, the s! creening, dissection, disinfection, processing, and preservation of the tissue by the Company, and the storage and shipment of the preserved tissue.

The human heart valves and cardiac patch tissues preserved by the Company are used in cardiac reconstruction and heart valve replacement surgeries. The Company preserves human aortic and pulmonary heart valves for implantation by cardiac surgeons. In addition, the Company preserves human cardiac patches for surgeons. The Company preserves human cardiac patches in three primarily anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. As of December 31, 2011, CryoLife shipped approximately 77,600 heart valves and cardiac patch tissues, including approximately 3,000 shipments during 2011.

The human vascular tissues preserved by the Company, including the CryoVein and CryoArtery, are used to treat a variety of vascular reconstructions, such as peripheral bypass, hemodialysis access and aortic infections. The Company preserves small diameter human saphenous vein conduits (3 millimeter to 6 millimeter) for use in peripheral vascular reconstructions. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass, hemodialysis access, or reconstruction within infected surgical areas. As of December 31, 2011, the Company shipped approximately 66,100 human vascular tissues, including approximately 4,500 shipments during 2011.

CryoLife�� product BioGlue, designed for cardiac, vascular, pulmonary, and general surgical applications, is a polymer based on bovine blood protein and an agent for cross-linking proteins. CryoLife distributes BioGlue throughout the United States and approximately 75 other countries. CryoLife distributes BioGlue for repair of soft tissues under conformite Europeene Mark Product Certification (CE Mark). CryoLife distributes BioGlue in Japan for use in the repair of aortic dissections.

CryoLife�� product, BioFoam, is a protein hydr! ogel biom! aterial with an expansion agent, which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and develops pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. CryoLife distributes BioFoam under CE Mark certification.

CryoLife�� product, PerClot, is an absorbable, powdered hemostatic agent used in surgery. PerClot particles have a molecular structure that absorbs water from blood, creating a high concentration of platelets, red blood cells, and coagulation proteins at the bleeding site, which accelerates the physiologic clotting cascade. PerClot is readily dissolved by saline irrigation and is totally absorbed within several days. PerClot is available in one gram, three gram and five gram sizes with a 100 millimeter or 200 millimeter applicator tip. PerClot Laparoscopic is available in one gram and three gram sizes with a 380 millimeter applicator tip.

The Company competes with St. Jude Medical, Inc., Medtronic, Inc., Edwards Life Sciences, Inc., Neovasc, Inc., LifeNet Health, Inc. W.L. Gore & Associates��Propaten, C.R. Bard, Inc., Hancock Jaffe Laboratories, Inc., Maquet, Inc., CorMatrix Cardiovascular, Inc., Baxter International, Inc., Johnson & Johnson Company, Covidien Ltd, NeoMend, Inc., Pfizer, Inc., Orthovita, Inc., King Pharmaceuticals, Inc., Ethicon, Inc., ZymoGenetics, Inc. and Nycomed.

Advisors' Opinion:

• [By Eric Volkman]

  CryoLife (NYSE: CRY  ) is putting some zip into its shares with a dividend boost. The company has declared a fresh quarterly distribution of $0.0275 per share, to be paid on June 21 to shareholders of record as of June 14. This marks the company's first-ever dividend increase -- the new amount is 10% higher than its three prior (and only) payouts, each of which totaled $0.025.

Best Medical Stocks For 2015: Alcobra Ltd (ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies. Advisors' Opinion:

• [By MONEYMORNING.COM]

  For example, a phase 3 clinical trial on metadoxine extended release as a treatment for adult attention deficit hyperactivity disorder (ADHD) will be finishing up at the end of this year. Positive data could give the stock a huge boost.

• [By Roberto Pedone]

  A biopharmaceutical stock that's starting to trend within range of triggering a big breakout trade is Alcobra (ADHD), which is engaged in the development and commercialization of its proprietary drug, MG01CI, to treat attention deficit hyperactivity disorder. This stock has been on fire so far in 2013, with shares up huge by 126%.

  If you take a look at the chart for Alcobra, you'll notice that this stock has been trending sideways and consolidating over the last month and change, with shares moving between $14.78 on the downside and $18.75 on the upside. Shares of ADHD have now started to uptrend a bit over the last few weeks, with shares moving higher from its low of $15.05 to its recent high of $18.45 share. That move has started to push shares of ADHD within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.

  Traders should now look for long-biased trades in ADHD if it manages to break out above its 50-day moving average of $17.79 a share, and then once it takes out some more key overhead resistance levels at $18.45 to $18.75 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 74,869 shares. If that breakout triggers soon, then ADHD will set up to re-test or possibly take out its next major overhead resistance levels at $22 to $24 a share. Any high-volume move above those levels will then give ADHD a chance to re-test or possibly take out its all-time high at $26.96 a share.

  Traders can look to buy ADHD off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support levels at $16.17 to $15.05 a share, or around $14.78 a share. One could also buy ADHD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Medical Stocks For 2015: Taro Pharmaceutical Industries Ltd (TARO)

Taro Pharmaceutical Industries Ltd., incorporated in 1959, is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�� primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.

Taro Israel manufactures more than 160 finished dosage form pharmaceutical products for sale in Israel and for export. It produces APIs used in the manufacture of finished dosage form pharmaceutical products. It markets and distributes generic products in the local Israeli market. Taro Israel�� primary product lines include dermatology, prescription and OTC semi-solid products (creams, ointments and gels) and liquids; cardiology and neurology, prescription oral dosage products; oral analgesics, both prescription and OTC, and OTC oral and nasal sprays and ophthalmic products.

Taro Canada manufactures more than 70 finished dosage form pharmaceutical products for sale in Canada and for export. It markets and distributes generic products in the local Canadian market. Its product line includes dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology, oncology, gastrointestinal and neurology: prescription oral and injects able dosage products, and allergy (antihistamine): OTC oral dosage products.

Taro U.S.A markets! and distributes generic products in the United States market. Its primary product lines include dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology and neurology: prescription oral dosage products, and other prescription and OTC products.

The Company competes with Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer/Wyeth, Valeant, Galderma, Merck/Schering-Plough, Teva Pharmaceuticals U.S.A., Mylan Laboratories, Perrigo Company, Ranbaxy Pharmaceuticals Inc., Sandoz Pharmaceuticals, Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Schering-Plough Canada, Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Bayer Inc., Bristol-Myers Squibb Canada, Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated, Pharmascience Inc., Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexxon Ltd., Rafa Laboratories Ltd., Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc.

Advisors' Opinion:

• [By Rich Smith]

  Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO  ) has a new CEO -- and a new Chairman of the Board, as well.

  On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi�has been appointed Chairman of its Board of Directors.

Best Warren Buffett Companies To Buy For 2015

The recent and very rapid rise in bond yields is changing the playing field for banks. As second-quarter earnings announcements rapidly approach, expect them to have an impact on both revenue and profit margins.�

Every bank will be affected, from the trillion-dollar megabanks like JPMorgan Chase (NYSE: JPM  ) and�Wells Fargo (NYSE: WFC  ) , to the community bank headquartered in your home town (or an index of community banks, like the SPDR S&P Regional Banking Index).

In the video below, Motley Fool contributor Jay Jenkins explains these critical issues and what they mean heading into the second-quarter earnings season.�

Many investors are scared about investing in big banking stocks after the crash, but the sector has one notable stand-out. In a sea of mismanaged and dangerous peers, it rises above as "The Only Big Bank Built to Last." You can uncover the top pick that Warren Buffett loves in The Motley Fool's�new report. It's free, so click here to access it now.

Best Warren Buffett Companies To Buy For 2015: Modine Manufacturing Co (MOD)

Modine Manufacturing Company (Modine), incorporated on June 23, 1916, specializes in thermal management systems and components, bringing heating and cooling technology and solutions to global markets. The Company is a global developer, manufacturer and marketer of heat exchangers and systems for use in on-highway and off-highway original equipment manufacturer (OEM) vehicular applications, and to a range of building, industrial, refrigeration and fuel cell markets. Its product lines include radiators and radiator cores, vehicular air conditioning, oil coolers, charge air coolers, heat-transfer packages and modules, building heating, ventilating and air conditioning (HVAC) equipment and exhaust gas recirculation (EGR) coolers. In February 2014, the Company announced that its Airedale International Air Conditioning Limited has acquired Barkell Limited, a manufacturer of custom built air handling units located in Consett (County Durham), United Kingdom. Effective March 1, 2014, Modine Manufacturing Co acquired Barkell Ltd.

North America, Europe, South America and Asia Segments

The original equipment- Asia, Europe and North America segments and South America segment serve the commercial vehicle, off-highway and automotive. Commercial vehicles products include powertrain cooling (PTC) (engine cooling modules, radiators, charge-air-coolers, condensers, fan shrouds, and surge tanks); on-engine cooling (exhaust gas recirculation (EGR) coolers, engine oil coolers, fuel coolers, charge-air-coolers and intake air coolers); oil coolers (transmission oil coolers and power steering coolers), and fuel coolers. Its customers include commercial, medium and heavy duty truck and engine manufacturers; bus, and specialty vehicle manufacturers.

Off-Highway�� products include powertrain cooling (engine cooling modules, radiators, condensers, charge-air-coolers, fuel coolers); auxiliary coolers (power steering coolers and transmission oil coolers); and on-engine cooling (EGR coolers,! engine oil coolers, fuel coolers, charge-air-coolers and intake air coolers). Its customers include construction and agricultural equipment, engine manufacturers and industrial manufacturers of material handling equipment, generator sets and compressors.

Automotive products include powertrain cooling (engine cooling modules, radiators, condensers, charge-air-coolers, auxiliary cooling (power steering coolers and transmission oil coolers), component assemblies, radiators for special applications) and on-engine cooling (EGR coolers, engine oil coolers, fuel coolers, charge-air-coolers and intake air coolers). Its customers include automobile, light truck and engine manufacturers.

The Company competes with Behr GmbH & Co. K.G., TitanX, Bergstrom, Inc., T.Rad Co. Ltd, Honeywell Inc, Dayco Ensa SA, Adams Thermal Systems Inc, AKG; Delphi Corporation; Denso Corporation, Zhejiang Yinlun Machinery Co., Ltd., ThermaSys Corp., Doowon; Valeo SA, Donghwan, Dana Corporation; Delphi Corporation, Showa and Visteon Corporation.

Commercial Products

The Commercial products include unit heaters (gas-fired, hydronic, electric and oil-fired); duct furnaces (indoor and outdoor); infrared units (high intensity and low intensity); hydronic products (commercial fin-tube radiation, cabinet unit heaters, and convectors); roof mounted direct- and indirect-fired makeup air units; unit ventilators; close control units for precise temperature and humidity control applications; chillers; ceiling cassettes and condensing units. Its customers include heating and cooling equipment manufacturers; construction contractors; wholesalers of plumbing and heating equipment; installers, and end users in a variety of commercial and industrial applications, banking and finance, data center management, education, hospitality, telecommunications, entertainment arenas, pharmaceuticals, hospitals, warehousing, manufacturing, and food and beverage processing.

The Company competes withLe! nnox Inte! rnational Inc. (ADP), ABB (Reznor), Mestek Inc. (Sterling), Emerson Electric Company (Liebert), Stulz; Schneider Electric (APC / Uniflair), United Technologies Corporation (Carrier), Johnson Controls, Inc. (York), Daikin (McQuay International), and Bard Manufacturing.

Advisors' Opinion:

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Modine Manufacturing (NYSE: MOD  ) .

• [By Seth Jayson]

  There's no foolproof way to know the future for Modine Manufacturing (NYSE: MOD  ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.

Best Warren Buffett Companies To Buy For 2015: Liberty Global Inc. (LBTYK)

Liberty Global, Inc. provides video, broadband Internet, and telephony services primarily in Europe and Chile. The company offers broadband services over cable distribution systems, including video, broadband Internet, and telephony; and video services through direct-to-home satellite, or through multichannel multipoint distribution systems. Its analog video services comprise basic and expanded basic programming; and digital cable services include basic and premium programming, digital video recorders, and high definition programming, as well as pay-per-view programming, such as video-on-demand and near video-on-demand. In addition, the company offers voice-over-Internet-protocol and circuit-switched telephony services, as well as mobile telephony services using third-party networks. Further, it owns programming networks that provide video programming channels to multi-channel distribution systems owned by the company and the third parties. As of December 31, 2011, the com pany owned and operated networks that passed 33,262,100 homes; and served 18,405,500 video subscribers, 8,159,300 broadband Internet subscribers, and 6,225,300 telephony subscribers. Liberty Global, Inc. was founded in 2004 and is based in Englewood, Colorado.

Advisors' Opinion:

• [By Monica Wolfe]

  Liberty Global PLC (LBTYK)

  John Burbank upped his stake by 376.63% during the second quarter. The guru purchased a total of 402,991 shares in the second quarter price range of $64.57 to $73.78, with an estimated average price of $69.23 per share. Since then the price per share has increased approximately 4.9%.

Top 10 Performing Companies To Invest In Right Now: Ishares Nasdaq Biotechnology (IBB)

iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, and which also meet other eligibility criteria. The Index is one of the eight sub-indices of the NASDAQ Composite, which measures all common stocks listed on The NASDAQ Stock Market, Inc.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By John Udovich]

  Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

• [By John Udovich]

  Small cap Biomed Realty Trust Inc (NYSE: BMR) is a real estate investment trust (REIT) offering an alternative way to gain exposure to the biotech or life sciences sector, meaning it might be worth taking a closer look at it along with a few benchmarks like the Vanguard REIT ETF (NYSEARCA: VNQ), iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI). Of course, it should be mentioned that REITs have had a rough ride lately�given all the ��apering��talk, but there is still a place for them in your portfolio with Biomed Realty Trust being one of the more unique offerings.

• [By Ben Levisohn]

  Shares of Regeneron Pharmaceuticals (REGN) have fallen 4.4% to $323.62 at 3:23 p.m., while�Biogen�(BIIB) has dropped 4% to $327.04 and�Gilead Sciences (GILD) has dipped 0.4% to $79.58. The iShares Nasdaq Biotechnology Index ETF�(IBB), meanwhile, has dropped 0.9% to $258.85 and the SPDR S&P Biotech ETF�(XBI) has declined 0.6% to $160.69. Suffice it to say, biotech investors don’t appear to be enjoying zero-G nearly as much as Kate Upton.

Best Warren Buffett Companies To Buy For 2015: Actuant Corp (ATU)

Actuant Corporation, incorporated on October 26, 1910, is a global diversified company that designs, manufactures and distributes a range of industrial products and systems to various end markets. The Company operates four business segments: Industrial, Energy, Electrical and Engineered Solutions. The Industrial segment is primarily involved in the design, manufacture and distribution of branded hydraulic and mechanical tools to the maintenance, industrial, infrastructure and production automation markets. The Energy segment provides joint integrity products and services, as well as rope and cable solutions to the global oil and gas, power generation and other energy markets. The Electrical segment is primarily involved in the design, manufacture and distribution of a range of electrical products to the retail DIY, wholesale, original equipment manufacturer (OEM), solar, utility, marine and other harsh environment markets. The Engineered Solutions segment provides engineered position and motion control systems to OEMs in various on and off-highway vehicle markets, as well as, a range of other products to the industrial and agricultural markets. In August 2013, the Company announced the completion of its acquisition of Viking SeaTech (Viking).

Industrial

The Industrial segment is a global supplier of branded hydraulic and mechanical tools to a broad array of end markets, including general maintenance and repair, industrial, infrastructure and production automation. The Company's primary products include hydraulic tools, engineered heavy lifting solutions, workholding (production automation) solutions and concrete stressing products. These hydraulic and mechanical tools are marketed primarily through the Company's Enerpac, Simplex, Precision Sure-Lock and Milwaukee Cylinder brand names. The high-force hydraulic and mechanical tools, including cylinders, pumps, valves, specialty tools and presses.

The Company's hydraulic tools operate at high pressures of approxim! ately 5,000 to 12,000 pounds per square inch and are generally sold by a diverse group of industrial and specialty fluid power distributors to customers in the infrastructure, mining, steel mill, cement, rail, oil and gas and general maintenance industries. Key industrial distributors include W.W. Grainger, Applied Industrial Technologies and MSC. In addition to providing a line of industrial tools, the segment also provides hydraulic systems (integrated solutions) to meet customer specific requirements for safe and precise control of movement and positioning. These customized heavy lifting solutions, which combine hydraulics, steel fabrication and electronic controls with engineering and application knowledge, are typically utilized in major infrastructure projects (bridges, stadiums, tunnels and offshore platforms) for heavy lifting, launching & skidding or synchronous lifting applications.

The Industrial segment has leveraged production and engineering capabilities to also offer a range of workholding products (work supports, swing cylinders and system components) that are marketed through distributors to the automotive, machine tool and fixture design markets. In addition, the segment designs, manufactures and distributes concrete pre- and post-tensioning products (chucks and wedges, stressing jacks and anchors) which are used by concrete tensioning system designers, fabricators and installers for the residential and commercial construction, railroad, bridge, infrastructure and mining markets.

Energy

The Energy segment provides technical products and services to the global energy markets, where safety, security, reliability and productivity are key value drivers. Products include joint integrity tools and connectors for oil & gas and power generation installations, as well as rope and cable solutions. In addition to these products, the Energy segment also provides manpower services, including machining, engineering and maintenance activities. The products and ! services ! of the Energy segment are distributed and marketed under various brand names (principally Hydratight, D.L. Ricci, Morgrip, Cortland, FibronBX, Puget Sound Rope, Biach, Selantic and Jeyco) to OEMs, maintenance and service organizations and energy producers in emerging and developed countries.

Joint integrity products include hydraulic torque wrenches, bolt tensioners and portable machining equipment. These products are used in the maintenance of bolted joints on oil rigs and platforms, wind turbines, refineries and pipelines, petrochemical installations, as well as fossil fuel and nuclear power plants. The Energy segment also provides rope and cable solutions that maximize performance, safety and efficiency for customers in various markets, including oil and gas, heavy marine, subsea, ROV and seismic. With its global design and manufacturing capabilities the Cortland business is able to provide customized synthetic ropes, heavy lift slings, specialized mooring, rigging and towing systems, electro-optical-mechanical cables and umbilicals to customers, including firms, such as CGG Veritas, Expro and Sercel. These products are utilized in critical applications, often deployed in harsh operating conditions (sub-sea oil & gas production, maintenance and exploration) and are required to meet robust safety standards. In addition custom designed products are also sold into a range of other niche markets including medical, security, aerospace and defense.

Electrical

The Electrical segment is involved in the design, manufacture and distribution of a broad range of electrical products to the retail DIY, OEM, electrical distribution, power transformation and harsh environment electrical markets. The Electrical segment sells its products through a combination of distributors, direct sales personnel and manufacturers' representatives. The Electrical segment provides the retail DIY market with a range of electrical tools and consumables, such as wire strippers, electrical meters,! connecto! rs, terminals, cable ties, staples and other wire management products and conduit bending equipment under the Gardner Bender, Del City and A.W. Sperry brands. These products are sold to retailers, such as Lowe's, The Home Depot, Menards, True Value and Ace Hardware, as well as numerous electrical distributors and OEM's.

The Electrical segment sells power transformation products in North America, including low voltage, single-phase dry type transformers and custom toroidal transformers under the Acme Electric brand name and high voltage switches under the Turner Electric brand name. These transformers are sold through electrical wholesale distributors, as well as directly to OEMs, such as Rockwell Automation, Eaton, Yaskawa and General Electric. Product offerings also include electrical components and systems for the harsh environment and marine markets under the Ancor, Marinco, Guest, Mastervolt and B.E.P Marine brand names. These products are primarily sold to various customers in the industrial, marine, power generation, industrial and retail markets, including West Marine, Applied Materials and Kohler. Solar products (primarily high efficiency solar inverters for residential and small commercial applications) are sold through local distributors and installers.

Engineered Solutions

The Engineered Solutions segment is a global designer and assembler of customized position and motion control systems and other industrial products to various transportation and other niche markets. This segment focuses on providing technical and engineered products, including actuation systems, mechanical power transmission products, engine air flow management solutions and rugged electronic instrumentation. Products in the Engineered Solutions segment are primarily marketed directly to OEMs through a technical sales organization. Approximately 55% of this segment's revenue comes from the vehicle systems product line (Power-Packer, Gits and Power Gear brands), which is sold to the t! ruck, aut! omotive, off-highway and specialty vehicle markets. Products include hydraulic cab-tilt and latching systems, which are sold to global heavy duty truck OEMs, such as Volvo, Iveco, Scania, Paccar-DAF and CNHTC and electro-hydraulic convertible top latching and actuation systems. The automotive convertible top actuation systems are utilized on both retractable soft and hard top vehicles manufactured by OEMs, such as Daimler, Volkswagen, Renault, Peugeot, BMW, Volvo and Nissan.

The Company's diesel engine air flow solutions, such as exhaust gas recirculation (EGR) systems, are used by diesel engine and turbocharger manufacturers to reduce emissions, improve fuel efficiency and horsepower. Primary end markets include heavy duty truck and off-highway equipment serving customers, such as Caterpillar, Cummins, Honeywell and Borg Warner. It also sells actuation systems to various specialty vehicle OEMs (principally in the defense, recreational vehicle and off-highway markets), such as Oshkosh and Fleetwood.

The Maxima Technologies tuck-in acquisitions of Turotest Medidores Ltda and CrossControl AB, along with the fiscal 2011 acquisition of Weasler Engineering have further diversified the geographic presence, technologies and end markets of the Engineered Solutions segment. The range of products, technologies and engineered solutions of Weasler Engineering, Maxima Technologies, Elliott Manufacturing, Sanlo and Nielsen Sessions comprise the other product line within the segment. Products include severe-duty electronic instrumentation (including displays and clusters, machine controls and sensors), power transmission products (engineered power transmission components, including drive shafts, torque limiters, gearboxes, torsional dampers and flexible shafts), and a comprehensive line of case, container and industrial hardware. These products are sold to a range of niche markets, including agricultural implement, lawn & turf, construction, forestry, industrial, aerospace, material handling! and secu! rity.

Advisors' Opinion:

• [By Ben Levisohn]

  General Electric’s earnings could also be a good sign for Actuant (ATU), United Technologies (UTX) and Honeywell International (HON), Dray says.

• [By Rich Duprey]

  Choosing to focus instead on its industrial, energy, and engineered solutions segments, diversified industrial specialist Actuant (NYSE: ATU  ) is jettisoning its electrical division, a move it expects to be completed in fiscal year 2014.

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Actuant (NYSE: ATU  ) .

• [By Monica Gerson]

  Analysts expect Actuant (NYSE: ATU) to report its Q4 earnings at $0.50 per share on revenue of $328.79 million. Actuant shares fell 0.21% to $38.76 in after-hours trading.

Best Warren Buffett Companies To Buy For 2015: Barratt Developments PLC (BDEV)

Barratt Developments PLC is a holding company. The Company�� principal activities consists of acquiring and developing land, planning, designing and constructing residential property developments and selling the homes it builds. The Company operates in two segments: housebuilding and commercial developments. The Company operates across a spectrum of the market from flats to family homes and urban regeneration schemes. The Company also has a focused commercial developments business. The Company builds a range of homes ranging from those for first-time buyers, to family homes, to high-rise flats and affordable housing. The Company�� housebuilding business trades under the Barratt Homes, David Wilson Homes and Ward Homes brands. The Company�� subsidiaries include BDW Trading Limited, BDW North Scotland Limited, David Wilson Homes Limited and Wilson Bowden Developments Limited. Advisors' Opinion:

• [By Inyoung Hwang]

  U.K. homebuilders declined as increasing bond yields spurred concern rising interest rates may hinder the housing recovery. Barratt Developments Plc (BDEV) sank 7.4 percent, Persimmon Plc fell 3.6 percent and Taylor Wimpey Plc lost 3.7 percent.

Best Warren Buffett Companies To Buy For 2015: Callaway Golf Co (ELY)

Callaway Golf Company, incorporated on May 7, 1999, together with its subsidiaries, designs, manufactures and sells golf clubs (drivers, fairway woods, hybrids, irons, wedges and putters) and golf balls, and also sells golf accessories (such as golf bags, golf gloves, headwear, towels, umbrellas and travel gear) under the Callaway Golf and Odyssey brand names. The Company sells pre-owned golf products through its Website, www.callawaygolfpreowned.com. In addition, it sells Callaway Golf and Odyssey products direct to consumers online through its Websites shop.callawaygolf.com and www.odysseygolf.com. The Company also licenses its trademarks and service marks in exchange for a royalty fee to third parties for use on golf related accessories, including apparel, footwear, eyewear, rangefinders and practice aids. Its products are sold in the United States and in approximately 100 countries around the world.

The Company designs, manufactures and sells golf clubs and golf balls, and designs and sells golf accessories. The Company�� products are designed for golfers of all skill levels, both amateur and professional. The Company�� principal products include Drivers, Fairway Woods and Hybrids; Irons; Putters; Golf Balls, and Accessories, Softgoods and Other. Drivers, Fairway Woods and Hybrids product category includes sales of the Company�� drivers, fairway woods and hybrid products, which are sold under the Callaway Golf brand. Irons include sales of the Company�� irons and wedges, which are sold under the Callaway Golf brand. Putters include sales of the Company�� putters, which are sold under the Odyssey brand. Golf Balls includes sales of the Company�� golf balls, which are sold under the Callaway Golf and Strata brands. Accessories, Softgoods and Other includes sales of golf bags, golf gloves, golf footwear, rangefinders, golf apparel, packaged club sets, headwear, towels, umbrellas, eyewear and other accessories, as well as sales of pre-owned products through www.callawaygolfpre! owned.com. Additionally, this product category includes royalties from licensing of the Company�� trademarks and service marks on products such as golf apparel, golf footwear, rangefinders and practice aids.

The Company competes with TaylorMade, Ping, Acushnet, Puma, SRI Sports Limited, Mizuno, Bridgestone, and Nike.

Advisors' Opinion:

• [By Charley Blaine]

  Callaway Golf (NYSE: ELY) was also up, gaining 19.83 percent to $8.70 after the company reported a narrower third-quarter loss and lifted its 2013 forecast. DA Davidson upgraded the stock from Neutral to Buy and lifted its price target from $7.50 to $11.

Best Warren Buffett Companies To Buy For 2015: iShares MSCI Ireland Capped ETF (EIRL)

iShares MSCI Ireland Capped ETF, formerly iShares MSCI Ireland Capped Investable Market Index Fund (the Fund), seeks investment results that correspond generally to the price and yield performance of the MSCI Ireland Investable Market 25/50 Index (the Index). The Index is a free-float adjusted market capitalization-weighted index designed to measure the performance of equity securities in the top 99% by market capitalization of equity securities listed on the stock exchanges in Ireland. BlackRock Fund Advisors (BFA) serves as the investment advisor of the Fund. BFA is a subsidiary of BlackRock Institutional Trust Company, N.A. Advisors' Opinion:

• [By Charles Sizemore]

  How does an investment manager reconcile all of the various prognostications he hears on a daily basis?Simple��gnore them.��eb Faber, Global ValueIf you��e never heard of Cambria Investment Management�� Meb Faber, then you have some serious catching up to do. I consider Faber one of the most innovative strategists in the business today, and I found his research on shareholder yield to be compelling enough to make the Cambria Shareholder Yield ETF (SYLD) a core, long-term holding in multiple ETF portfolios I manage. (For readers unfamiliar with the term, ��hareholder yield��is a holistic measure of shareholder friendliness that includes dividends paid, shares repurchased, and debt repaid.)Faber�� latest book, Global Value: How to Spot Bubbles, Avoid Market Crashes, and Earn Big Returns in the Stock Market, provides the research underpinnings for Cambria�� latest ETF offering, the Cambria Global Value ETF (GVAL).Faber is a ��uant��who ignores the news of the day and instead focuses on the raw numbers. At its core, Global Value is a roadmap for implementing the value investing concepts originally espoused by Benjamin Graham and David Dodd in their 1934 classic Security Analysis in a systematic, quantitative manner.Specifically, Faber uses the cyclically-adjusted price/earnings ratio (��APE��, a metric popularized by Yale economist Robert Shiller, as a valuation tool to rank countries. In Faber�� model, an investor buys the stocks of the cheapest countries as ranked by the CAPE.The CAPE divides the current market price by the average of annual earnings across the economic cycle, with 10 years being the most popular time interval.Why? Because using a single year�� earnings can massively skew the results based on where you are in the economic cycle. As an example, a collapse in earnings in 2008-2009 would have made the S&P 500 look expensive had you used a simple P/E calculation with 2008 earnings numbers, even though the market had los

Best Warren Buffett Companies To Buy For 2015: IMF (AUSTRALIA)

IMF (Australia) Ltd investigates, manages, and funds litigation and arbitration claims primarily in Australia and the United States. Its litigations include commercial claims, insolvency claims, and group actions. The company offers funding for litigation and investigations preliminary to litigation; payment of adverse costs orders; strategic planning, monitoring, and managing of litigation; factual investigation, including asset tracing; and assistance in facilitating settlements and maximizing the value of each claim. IMF (Australia) Ltd is based in Sydney, Australia.

Advisors' Opinion:

• [By GURUFOCUS]

  News Corp. (0.4%) (NWSA - $16.06 (0.3%) NWS - $16.43 (0.1%) - NASDAQ)(NWSA), based in New York, operates in five segments: 1) News and information services ��U.S., United Kingdom, and Australian publishing businesses, including The Wall Street Journal, the Times of London, and the New York Post, along with News America Marketing Corp., a leading provider of free standing inserts (FSIs or cents off coupons); 2) Cable network programming ��Fox Sports Australia; 3) Digital real estate services ��a 62% interest in publicly traded REA Group Ltd. (Australia); 4) Book publishing ��Harper Collins, one of the largest English language publishers in the world; and 5) Other ��primarily the company's K-12 education business ��Amplify. On June 28, 2013, 'old News' Corp. (now Twenty-First Century Fox Inc. (2.4%)) spun off most of its non entertainment assets ('new News') to holders on a one for four basis. We estimate that the company will generate about $800 million of EBITDA on $8.7 billion of revenues for the year ending June 30, 2014.�